Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim says growth is due to medicines

Boehringer Ingelheim says growth is due to medicines

22nd April 2009

Boehringer Ingelheim achieved its goals for last year largely due to its prescription medicines, it has claimed.

Compared to the pharmaceutical market as a whole, the company grew stronger and its net sales rose from 10.9 billion euros (9.6 billion pounds) in 2007 to 11.6 billion euros.

Some 79 per cent of the business’ net sales came from prescription medicines.

Its drug Spriva ? designed to treat chronic obstructive pulmonary disease ? achieved a turnover of more than two billion euros and treated over ten million patients.

Engelbert Tjeenk Willink is responsible for the corporate board division of the company’s pharmaceutical marketing and sales.

Mr Willink commented: “Our growth in 2008 again gratifyingly exceeded the world pharmaceutical market in all three regions.

“Our innovative products have good potential for the future.”

Member of the board of directors Andreas Barner added the firm is confident it can continue the success over the next 12 months, with further strong sales in its prescription medicines.

Last month, Boehringer Ingelheim completed phase III clinical trials of its randomised evaluation of long-term anticoagulant therapy study.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.